RecruitingNCT07785180

A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy

Retrospective Study of Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated With Chemotherapy Agents

Sponsor

Stemline Therapeutics, Inc.

Enrollment

140 participants

Start Date

Oct 17, 2025

Study Type

OBSERVATIONAL

Conditions

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Summary

The main goal of this study is to investigate the effectiveness and safety of chemotherapy agents in the treatment of participants with BPDCN and to provide comparator arm data to the prospective ELZONRIS registry study (STML-401-0521).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Chemotherapy for people with blastic plasmacytoid dendritic cell neoplasm (bpdcn). The study is currently recruiting participants at 67 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGChemotherapy

Several chemotherapy regimens can be considered (acute myeloid leukemia-like, acute lymphocytic leukemia-like, lymphoma-like). The choice of the regimen, as well as dosing and schedules, are based on the institution's and the health care provider's preferences. No study medication will be provided by the sponsor during this study.

Locations(67)

Aarhus University Hospital

Aarhus, Denmark

Odense University Hospital

Odense, Denmark

Centre Hospitalier Universitaire Besancon

Besançon, France

Hôpital Avicenne

Bobigny, France

Centre Hospitalier Universitaire de Bordeaux - Hôpital Haut-Lévêque

Bordeaux, France

Henri Mondor University Hospital

Créteil, France

Centre Hospitalier Universitaire de Nice

Nice, France

Saint-Antoine Hospital

Paris, France

Saint-Louis Hospital

Paris, France

Centre Hospitalier Universitaire Poitiers

Poitiers, France

Centre Hospitalier Universitaire de Tours

Tours, France

Gustave Roussy

Villejuif, France

Klinikum Bremen-Mitte gGmbH

Bremen, Germany

Klinikum Chemnitz gGmbH

Chemnitz, Germany

Uniklinikum Leipzig

Leipzig, Germany

University Hospital Schleswig Holstein Campus Lübeck

Lübeck, Germany

Klinikum rechst der Isar, Technische Universität München

Munich, Germany

Klinikum Oldenburg AöR

Oldenburg, Germany

Uniklinikum Würzburg

Würzburg, Germany

Evaggelismos Hospital, Dept. Hematology-Lymphoma and BMT Unit

Athens, Greece

National and Kapodistrian University of Athens, General Hospital of Athens

Athens, Greece

University of Patras

Pátrai, Greece

A.O. SS Antonio e Biagio e Cesare Arrigo

Alessandria, Italy

Azienda Ospedaliero Universitaria Consorziale Policlinico

Bari, Italy

IRCCS Azienda Ospedaliero Universitaria di Bologna

Bologna, Italy

ASST Spedali Civili

Brescia, Italy

A.O.U. Policlinico Rodolico San Marco

Catania, Italy

A.O.U. Careggi

Florence, Italy

ASST Grande Ospedale Metropolitano Niguarda

Milan, Italy

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico

Milan, Italy

IEO Istituto Europeo di Oncologia

Milan, Italy

Azienda Ospedaliera Universitaria Federico II

Naples, Italy

A.O.U. Maggiore della Carità

Novara, Italy

Azienda Ospedale-Università di Padova

Padova, Italy

A.O.O.R. Villa Sofia- Cervello

Palermo, Italy

Fondazione IRCCS Policlinico San Matteo

Pavia, Italy

Presidio Ospedaliero Santo Spitiro

Pescara, Italy

Ospedale S. Maria delle Croci

Ravenna, Italy

A.O.U. Sant'Andrea

Roma, Italy

Fondazione Policlinico Universitario A. Gemelli IRCCS

Roma, Italy

Policlinico Tor Vergata

Roma, Italy

A.O.U. San Giovanni di Dio e Ruggi D'Aragona

Salerno, Italy

A.O.U. Città della Salute e della Scienza

Torino, Italy

AO Ordine Mauriziano di Torino

Torino, Italy

ASUFC P.O. Santa Maria della Misericordia

Udine, Italy

Amsterdam UMC

Amsterdam, Netherlands

UMC Groningen

Groningen, Netherlands

Radboud Universitair Medisch Centrum

Nijmegen, Netherlands

Institute of Hematology and Transfusion Medicine

Warsaw, Poland

Maria Sklodowska-Curie National Research Institute of Oncology

Warsaw, Poland

Hospital de Santa Maria

Lisbon, Portugal

Hospital General de Albacete

Albacete, Spain

Hospital General Dr Balmis

Alicante, Spain

Hospital Germans Trias i Pujol

Badalona, Spain

Hospital Universitario De Burgos

Burgos, Spain

Hospital San Pedro de Alcántara

Cáceres, Spain

Hospital Universitario Reina Sofia

Córdoba, Spain

Fundacion Jimenez Diaz

Madrid, Spain

Hospital Universitario 12 de Octubre

Madrid, Spain

Hospital Universitario Ramón y Cajal

Madrid, Spain

MD Anderson Cancer Center

Madrid, Spain

Hospital Universitario Central de Asturias

Oviedo, Spain

Hospital La Fe

Valencia, Spain

Sahlgrenska University Hospital - Section for hematologi and coagulation

Gothenburg, Sweden

King's College Hospital

London, United Kingdom

University College London Hospitals

London, United Kingdom

Oxford University Hospitals NHS Foundation Trust

Oxford, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07785180

Related Trials

A Registry-study of ELZONRIS in Participants With BPDCN

NCT07785154

Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients

NCT0700705234 locations

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry

NCT0543097122 locations

CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial

NCT067658761 location

Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT060064031 location